Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 13/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247876 | 0.87 | DHODH (0.65) | DHODHNPSR1MRGPRX4 | |
| SCHEMBL247329 | 0.87 | DHODH (1.00) | DHODHNPSR1NPC1MAPTRAB9A | |
| SCHEMBL248244 | 0.86 | DHODH (0.71) | DHODHNPSR1MRGPRX4 | |
| SCHEMBL17253572 | 0.82 | DHODH (0.77) | DHODHNPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL290914 | 0.81 | DHODH (0.89) | DHODHNPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13743194 | 0.79 | DHODH (0.54) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3913298 | 0.76 | DHODH (0.67) | DHODHNPSR1 | |
| SCHEMBL517712 | 0.76 | DHODH (0.85) | DHODHNPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19417319 | 0.75 | DHODH (0.50) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3924492 | 0.75 | DHODH (0.74) | DHODHNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | claimed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | disclosed |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| EP-2966058-B1 | NOVEL CALCIUM SALTS OF COMPOUND AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-09-07 | — | — | US | disclosed |
| CN-1525954-A | Novel compounds useful as anti-inflammatory, immunomodulatory and antiproliferative agents | 4SC�ɷݹ�˾ | 2004-09-01 | — | — | CN | disclosed |
| EP-1392642-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003006425-A9 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-02-26 | — | — | WO | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006425-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | DHODH 1/4885NPSR1 4091/4885NPC1 1461/4885 |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, HADHA | DHODH 1/4885NPSR1 3836/4885NPC1 1568/4885 |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885NPSR1 4735/4885NPC1 4279/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | DHODH 1/4885NPSR1 2838/4885NPC1 830/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885NPSR1 4735/4885NPC1 4279/4885 |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885NPSR1 2838/4885NPC1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.